Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations

NCT06906562 is registered in ClinicalTrials.gov with Sameek Roychowdhury as lead sponsor.

NCT NCT06906562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations
Lead sponsor
Sameek Roychowdhury
Phase
Phase 2
Overall status
Recruiting
Start date
August 26, 2025
Completion date
December 31, 2028
Enrollment
40 (estimated)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic carcinoma, metastatic pancreatic carcinoma, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8